Determination of bromazepam in plasma and of its main metabolites in urine by reversed-phase high-performance liquid chromatography.
A high-performance liquid chromatographic method for the determination of bromazepam in plasma and of its main metabolites in urine is described. The unchanged drug is extracted from plasma with dichloromethane, using Extrelut 1 extraction tubes. The residue from this extract is subsequently analysed by reversed-phase high-performance liquid chromatography with ultraviolet detection (230 nm). The limit of detection is 6 ng/ml of plasma, using a 1-ml specimen. For the determination of the metabolites, the urine samples are incubated to effect enzymatic deconjugation and are then extracted with dichloromethane. Following two clean-up steps (back extractions), the final residue is analysed on the same reversed-phase system as the plasma samples. The limit of detection for the two metabolites is 200 ng/ml.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism*; D001960:Bromazepam / Q000031:analogs & derivatives / Q000378:metabolism* / Q000652:urine; D002417:Cattle; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005966:Glucuronidase / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D006900:Hydroxylation; D008099:Liver / Q000201:enzymology; D011725:Pyridines / Q000652:urine; D013056:Spectrophotometry, Ultraviolet
D014151:Anti-Anxiety Agents; D011725:Pyridines; C042089:3-hydroxybromazepam; C043575:2-(2-amino-5-bromobenzoyl)pyridine; C043574:N-methylbromazepam; D005966:Glucuronidase; D001960:Bromazepam